In recent years, affected by the drastic changes in the pharmaceutical industry, multinational pharmaceutical companies have begun to adjust their development strategies and talent structures
on a large scale.
Against this backdrop, executive mobility in multinational companies has also begun to accelerate
.
Within a month, a large number of well-known pharmaceutical companies announced new personnel appointments
.
Biogen
On November 10, Biogen announced that the Board of Directors has appointed Christopher A.
Viehbacher as President and Chief Executive Officer (CEO) and Board of Directors, effective
November 14.
Viehbacher has extensive international experience
working in both large pharmaceutical companies and entrepreneurial biotechnology companies.
After 20 years at GlaxoSmithKline, he spent 6 years as Global CEO
at Sanofi.
During this time, he helped Sanofi overcome patent losses for most of its portfolio and tap new sources
of growth for the company.
Boehringer Ingelheim
Since Mehdi Shahidi, MD, left in February, Boehringer Ingelheim has been looking for a new chief medical officer (CMO
).
On November 3, former Novartis executive Lykke Hinsch Gylvin said on LinkedIn that she would join Boehringer Ingelheim as CMO and head of global medicine
.
It is understood that the new CMO Lykke Hinsch Gylvin previously served as vice president of global medical franchise and head of
neuroscience at Novartis.
Prior to that, she spent four years at AstraZeneca and held leadership positions
at Roche, Novo Nordisk and Lundbeck.
Merck
On October 27, Merck announced that the Board of Directors unanimously agreed to elect Robert M.
Davis as Chairman of the Board of Directors, effective December 1, 2022; Kenneth C.
Frazier, the former chairman of the board, plans to officially retire
on November 30, 2022.
It is understood that since joining Merck in 1992, Vorvitzer has served the company for 30 years
.
In 2021, Flevitzer stepped down as CEO of Merck on July 1, and was replaced by the company's former CFO Dai Fucai
.
GSK
On October 25, a number of foreign media reported that Roger Connor, president of GSK Vaccines and Global Health, was about to leave
.
At the same time as Roger's departure, GSK also made changes
to some executives.
Among them, Chief Commercial Officer Luke Miels will have overall responsibility for the strategic commercial product development of vaccines (in collaboration with R&D and supply), while continuing to be responsible for the development of strategic product development for specific and generic drugs and commercialization
of the product portfolio.
RIgis Simard, president of global supply chain, is responsible for the supply
of vaccines and medicines.
Deborah Waterhouse, CEO of ViiV Healthcare, will have overall responsibility for GSK Global Health
.
In addition to this executive change, a month ago, GSK appointed former Burberry CFO and operating officer Julie Brown as the company's chief financial officer, replacing the retiring Iain Mackay
.
Novartis
On October 23, Novartis announced that Tian Yu will return to Novartis on November 10, 2022 as the head of immunotherapy in China of Novartis Innovative Drugs, based in Shanghai
.
Prior to joining Novartis, Tian was the head of Merck's China Oncology Business Unit, where she successfully led CRETRUDA's private market strategy
.
Upon his return to Novartis, he will become a member of the management team of Innovative Drugs China and report directly to Zhang Ying
, President of Novartis Innovative Drugs China.
In this role, Tian will continue to drive the growth of Keshan Ting and Thrive, unleash the potential of the county, and benefit patients in the broader Chinese market with our innovative product portfolio
.
epilogue
In addition to frequent changes in senior management, the pace of staff reduction in multinational pharmaceutical companies is also accelerating
.
According to incomplete statistics, since 2022, more than 80 foreign biotechnology companies have reduced their workforce
.
Among them, there are many large pharmaceutical companies
such as Eisai, Biogen, Novartis, Sanofi, Merck, Gilead, and Daiichi Sankyo and so on.
In this regard, the industry believes that in the future, under the background of intensifying changes in the policy environment of the pharmaceutical industry and continuous strategic adjustment of enterprises, changes in senior management and layoffs will become the
norm.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
